ALANINE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
89.0 -0.6 2 2 63.0 1 0.67
UNII
OF5P57N2ZX
CAS
56-41-7
SYNONYMS
  • Alanine
  • L-2-Aminopropanoic Acid
  • L-Alanine
  • Alanine [inn]
  • Alanine [usan]
  • Alanine [ep]
  • Alanine [usp]
  • L-Alanine [jan]
  • Alanine [mi]
  • Alanine [inci]
  • L-Alanine [fcc]
  • Alanine [ii]
  • Alanine [hsdb]
  • L-Alanine [usp-Rs]
  • Alanine [who-Dd]
  • Alanine [vandf]
  • Nsc-206315
ZINC ID(s)
Availability
Present in 101 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT00008801 hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure Phase 1/Phase 2 Active, Not Recruiting
NCT00309439 ALA and Prostate Cancer Phase 2 Active, Not Recruiting
NCT02145949 2015-01-01 Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults Phase 2 Recruiting
NCT02281136 2014-12-01 MUSE Study of Levulan Kerastick Phase 2 Not Yet Recruiting
NCT02209012 2014-08-01 Twelve Month Follow-Up of CP0108 Phase 3 Recruiting
NCT02137785 2014-05-01 Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Phase 3 Recruiting
NCT02144077 2014-01-01 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy Phase 3 Recruiting
NCT01944059 2013-11-01 Theramine® in the Prevention of Migraine Headache Phase 4 Active, Not Recruiting
NCT01893203 2013-08-01 Treating Actinic Keratoses With Natural Daylight PDT: Comparing Two Light Sensitizers (ALA and MAL) Phase 4 Completed
NCT01838694 2013-07-01 Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. Phase 1/Phase 2 Recruiting
NCT01898416 2013-06-01 Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors Phase 2 Recruiting
NCT01811121 2013-02-01 MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS Phase 3 Recruiting
NCT01522677 2012-01-01 A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer Phase 1/Phase 2 Recruiting
NCT01478126 2012-01-01 Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass Phase 3 Completed
NCT01475955 2011-12-01 Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK) Phase 2 Completed
NCT01458587 2011-11-01 Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK) Phase 2 Completed
NCT01445691 2011-09-01 More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery Phase 2 Recruiting
NCT01310868 2011-05-01 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma Phase 2 Active, Not Recruiting
NCT01267253 2011-04-01 Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2 Suspended
NCT00628381 2011-01-01 L-citrulline Supplementation During Sepsis Phase 3 Not Yet Recruiting
NCT01253668 2010-11-01 Brivanib Metastatic Renal Cell Carcinoma Phase 2 Completed
NCT01502280 2010-11-01 Fluorescence-guided Surgery for Low- and High-grade Gliomas Phase 3 Recruiting
NCT01459393 2010-11-01 Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment Phase 3 Completed
NCT01611584 2010-06-01 A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer Phase 1 Withdrawn
NCT01051999 2010-02-01 Glutamine Supplementation in Cystic Fibrosis Phase 2 Completed
NCT00888173 2009-07-01 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Phase 2 Active, Not Recruiting
NCT00798252 2009-03-01 Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers Phase 1 Active, Not Recruiting
NCT01259544 2009-01-01 BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency Phase 2 Completed
NCT00948324 2008-06-01 Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes Phase 4 Enrolling By Invitation
NCT00640471 2008-05-01 Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer Phase 3 Completed
NCT01185210 2007-09-01 Investigation of Alanine in Fructose Intolerance: A Dose Ranging Study Phase 2 Recruiting
NCT00706433 2007-03-01 Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne Phase 2 Completed
NCT00378508 2006-09-01 Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes Phase 2 Active, Not Recruiting
NCT00239720 2006-03-01 hOKT3gamma1 (Ala-Ala) for the Treatment of Psoriatic Arthritis Phase 2 Terminated
NCT00073255 2003-06-01 Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM) Phase 1 Completed
NCT00164268 2002-10-01 Ke Ala Lokahi Demonstration Project for Sexual and Domestic Violence Prevention Phase 1 Completed
NCT00806572 2002-05-01 Treatment With hOKT3gamma1(Ala-Ala) in T1DM Phase 2 Terminated
NCT00285194 2000-04-01 hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients Phase 1/Phase 2 Completed
NCT00241670 1999-10-01 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Phase 3 Completed
NCT00410839 1999-06-01 Studies of the Prevention of Atrial Fibrillation by ALA Phase 2 Active, Not Recruiting

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Iv(infusion) Solution, Injection 0.21%

More Information

Usage Over Time

Comments